Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.8968
+0.08149.98%
Post-market: 0.93000.0332+3.70%19:58 EDT
Volume:2.54M
Turnover:2.27M
Market Cap:165.42M
PE:-1.07
High:0.9500
Open:0.8998
Low:0.8421
Close:0.8154
Loading ...

Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Aa Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Severe-to-Very Severe Alopecia Areata

THOMSON REUTERS
·
26 Feb

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

PR Newswire
·
26 Feb

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes

TIPRANKS
·
25 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (FMS), Herbalife (HLF) and Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

BRIEF-Nektar Announces Clinical Trial Agreement To Evaluate Rezpegaldesleukin

Reuters
·
24 Feb

Nektar Therapeutics Partners With TrialNet to Test Rezpegaldesleukin in Type 1 Diabetes

MT Newswires Live
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients With New Onset Type 1 Diabetes Mellitus

THOMSON REUTERS
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

PR Newswire
·
24 Feb

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

PR Newswire
·
24 Feb

B.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
17 Feb

Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop

Simply Wall St.
·
10 Feb

Nektar Says FDA Grants Fast-Track Designation to Atopic Dermatitis Treatment

MT Newswires Live
·
10 Feb

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
10 Feb

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

PR Newswire
·
10 Feb